Neurofibromatosis

(redirected from Neurofibromatoses)
Also found in: Dictionary, Thesaurus, Medical.

neurofibromatosis

[¦nu̇r·ō·fī‚brō·mə′tō·səs]
(medicine)
A hereditary disease characterized by the presence of neurofibromas in the skin or along the pathway of peripheral nerves. Also known as fibroma molluscum; multiple neurofibroma; multiple neurofibromatosis; neurinomatosis; neuroblastomatosis; Smith-Recklinghausen's disease.

Neurofibromatosis

 

a disease characterized by multiple tumors of the nerve trunks. It is also called Recklinghausen’s disease after the German pathologist F. Recklinghausen (1833–1910), who first described the disease in 1882.

Neurofibromatosis usually arises in the nerves of the skin, bones, and endocrine glands. It is believed that neurofibromatosis occurs because of a disturbance in the development of the ectodermal germ layer in the embryo; however, the causes and developmental mechanisms of the disease have not been elucidated. Multiple soft tumors of various sizes appear on or within the skin. The tumors are covered with yellow to dark brown pigmentation spots of various sizes. Changes in the bone structure can arise in neurofibromatosis, and the spine can be deformed even to the point of curving. Neurofibromatosis may also affect the central nervous system; in such cases, physical and mental underdevelopment are sometimes observed.

References in periodicals archive ?
The report reviews pipeline therapeutics for Neurofibromatoses by companies and universities/research institutes based on information derived from company and industry-specific sources
The report reviews key players involved Neurofibromatoses therapeutics and enlists all their major and minor projects
Coverage of the Neurofibromatoses pipeline on the basis of route of administration and molecule type.
Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses.
The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The report reviews pipeline therapeutics for Neurofibromatoses Type II by companies and universities/research institutes based on information derived from company and industry-specific sources
A review of the Neurofibromatoses Type II products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
A review of the Neurofibromatoses Type I (Von Recklinghausen's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.